BioHarvest Sciences Inc. develops plant-based compounds through its proprietary Botanical Synthesis technology platform, which is designed to grow plant compounds without cultivating the underlying plant. Company news centers on two business verticals: a direct-to-consumer products business built around proprietary nutraceutical health and wellness products, including VINIA, and a CDMO business serving customers seeking novel plant-based compounds.
Recurring updates include financial results, product commercialization, direct-to-consumer growth, CDMO development programs, and applications of the platform in areas such as nutraceuticals and fragrance molecules. BioHarvest also reports governance and leadership changes, equity-based compensation actions, financing activity, and conference participation tied to its public-company profile.
BioHarvest Sciences (BHST) has advanced its proprietary Olive Cell composition to commercial readiness and made it available for licensing through its contract development and manufacturing business.
The olive-derived composition has completed development, large-scale manufacturing work and the applicable self-affirmed U.S. Generally Recognized as Safe (GRAS) process. Its manufacturing facility is ready to produce it according to a future customer's or partner's requirements and timing.
Previously reported preliminary laboratory tests showed reductions of up to 37% in lipid accumulation in HepG2 human liver cells versus controls and up to 50% in collagen type I accumulation in LX-2 hepatic stellate cells. Both effects were dose-dependent; human efficacy is not established. BioHarvest intends to pursue licensing, manufacturing, royalties, co-development and, where appropriate, ownership participation across its asset portfolio.
BioHarvest Sciences (BHST) and Tate & Lyle reached a development milestone demonstrating production of their targeted next-generation sweetening solution. The programme demonstrated that BioHarvest's Botanical Synthesis platform can produce the targeted solution. The companies said development activities continue to advance in line with expectations. The milestone concerns the ongoing development programme, rather than a commercial launch.
BioHarvest describes the platform as having the potential to reduce dependence on traditional agriculture for plant-derived ingredients, improve consistency and supply reliability, and reduce some production time, labour and natural-resource requirements. These potential benefits are distinct from the demonstrated ability to produce the targeted sweetening solution.
BioHarvest Sciences (BHST) authorized a repurchase program for up to 1,133,392 common shares under a normal course issuer bid.
The limit represents 5% of outstanding common shares. The program cannot begin earlier than 5 days after the announcement. It will end at the earliest of 12 months from its start, the purchase of the maximum authorized shares, or BioHarvest's decision to terminate it sooner. Purchases will be made through Nasdaq in the open market at prevailing prices, and all shares bought under the program will be retired.
Management will determine the number of shares purchased, their timing and price, subject to applicable securities laws. BioHarvest's board believes the market price may not fully reflect the value of the business and its future growth prospects.
BioHarvest Sciences (BHST) launched single-dose VINIA Daily Chews, a chewable format of its proprietary red-grape cell composition, to expand VINIA’s addressable market and demonstrate the commercial versatility of its Botanical Synthesis platform.
Each individually packaged chew delivers 400 mg of VINIA, matching the daily amount in the company’s capsule format, plus 6 mg of piceid resveratrol, a dosage that has been clinically shown to increase arterial dilation and improve blood flow. The chewable format targets consumers who prefer convenient alternatives to capsules and is intended to support broader demographics, more usage occasions, and stronger daily-habit formation under the VINIA brand.
BioHarvest positions VINIA as a live validation of its Botanical Synthesis CDMO capabilities, showing how plant-cell compositions produced as a natural, non-GMO powder can be scaled and converted into differentiated consumer products. VINIA Daily Chews are now available for purchase on www.vinia.com.
BioHarvest Sciences (BHST)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, in New York City.Chief Executive Officer Zaki Rakib is scheduled to deliver an in-person company presentation at 4:00 PM ET in the Roswell room (4th Floor) at the Lotte New York Palace Hotel, and will also hold one-on-one investor meetings during the September 14–16 conference. A live webcast of the presentation will be publicly accessible online via the provided link, while in-person attendance requires conference registration. Registered in-person and virtual attendees may request individual meetings through their H.C. Wainwright representative.
BioHarvest Sciences (BHST) plans a dual listing of its ordinary shares on the Tel Aviv Stock Exchange, alongside Nasdaq, with trading on TASE expected to begin on September 8, 2026.
The company has requested registration on TASE of all 22,667,842 outstanding common shares, up to 4,516,021 shares reserved for its Equity Incentive Plan, and 610,742 shares issuable upon exercise of existing investor warrants. Any future additional share listings will require TASE approval. Shares are expected to trade under the English symbol BHST and an alternative Hebrew symbol, with future EDGAR filings to be concurrently filed via Israel’s MAGNA system.
BioHarvest (NASDAQ: BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year-over-year, with a gross margin of 58% versus 59% last year. Operating loss was $2.5 million and net loss $3.7 million, while Adjusted EBITDA loss widened to $1.6 million.
The company secured its first CDMO manufacturing and supply agreement with a UAE-based customer to support an anticipated 20-ton production program of a rare, high-value botanical fragrance, with limited output expected from 1H 2027. According to BioHarvest, cash and bank deposits reached $16.25 million as of June 30, 2026.
BioHarvest received a $1.4 million Israel Innovation Authority grant, advanced a $1.125 million saffron program to Stage 2, and expanded its Tate & Lyle sweetener collaboration. The VINIA D2C business grew revenue 2% year-over-year with about 95,000 active customers, but full-year VINIA revenue and EBITDA guidance were reduced as spending is redirected to manufacturing capacity and CDMO investments.
BioHarvest (NASDAQ: BHST) announced an exclusive manufacturing and supply agreement with its existing, undisclosed UAE fragrance partner to produce a rare, endangered fragrance plant cell culture through 2027 and 2028. The deal extends a prior agreement and designates BioHarvest as the exclusive manufacturing partner for the partner’s proprietary cell culture composition.
The company plans to begin limited production in the first half of 2027, with anticipated total volumes of up to 20 metric tons, subject to final product specifications. Contingent on successful delivery, BioHarvest estimates it could recognize $20–$30 million in revenue at completion. The project builds on Stage 1 and Stage 2 R&D milestones reached earlier in the year and leverages BioHarvest’s Botanical Synthesis platform to supply sustainable, consistent rare fragrance molecules. BioHarvest also retains a 20% ownership stake in the developed composition, supporting its entry into the premium fragrance segment, which it cites as a $23 billion part of the $58.9 billion global scents and fragrances market.
BioHarvest Sciences (NASDAQ: BHST) announced that CEO Zaki Rakib will present at the Canaccord Genuity 46th Annual Growth Conference, held August 11-13, 2026, in Boston, Massachusetts. The company presentation is scheduled for Wednesday, August 12, 2026, at 1:00 p.m. ET.
The in-person session will take place in Abigail Adams C at the InterContinental Hotel in Boston, with a publicly accessible live webcast available to online pre-registrants at the provided link. According to BioHarvest, investors can request one-on-one meetings with the company through their Canaccord Genuity representative. The conference connects global institutional investors with growth companies across Technology, Healthcare & Life Sciences, Sustainability, Industrials, and Consumer & Retail sectors.
BioHarvest Sciences (NASDAQ: BHST) announced it will report its second quarter 2026 financial results before market open on Tuesday, August 11, 2026. Management will host a conference call and live webcast at 8:00 AM Eastern Time to review results, business operations, and the 2026 strategy and growth plan.
The webcast can be accessed at https://events.q4inc.com/attendee/553034064, with replay available later in the Investor Relations/Events & Presentations section of the company’s website. Shareholders and investors are invited to join CEO Zaki Rakib and the team for the update.